We're Here for You!
The IMF is dedicated to improving the quality of life of myeloma patients while working toward prevention and a cure.
I am a...
IMF Chairman of the Board Dr. Brian G.M. Durie provides answers to growing concerns from myeloma patients because of the omicron spread. Get firsthand information about the omicron variant and helpful advice on COVID-19 testing, vaccines, boosters, and the like.
On December 29, 2021, the Janssen Pharmaceutical Companies of Johnson & Johnson announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking approval of teclistamab for the treatment of patients with relapsed or refractory (R/R) multiple myeloma. Teclistamab is an investigational, off-the-shelf, T-cell redirecting, bispecific antibody targeting both B-cell maturation antigen (BCMA) and CD3.
Do you want to receive the latest myeloma news and research for free, directly in your email inbox? You can with the Myeloma Minute!
The Myeloma Minute includes: Blogs and videos from Dr. Brian G.M. Durie, information about drug recalls, the latest FDA approvals, research announcements, patient support events, regional educational outreach, advocacy action, and so much more.
Subscribe now to receive weekly email newsletters with up-to-the 'minute' information about multiple myeloma.
Start your New Year off with a resolution that impacts the lives of myeloma patients. Volunteer fundraisers help raise multiple myeloma awareness and much-needed funding for the IMF's essential research, patient education, support, and advocacy programs.
Starting a member fundraiser is easy and fun! The Team at the IMF is with you every step of the way! Reach out to the IMF's Senior Director of Member Events, Suzanne Battaglia at [email protected] to get assistance with organizing your fundraiser now.
Need to stay informed about the news that impacts myeloma patients, but don’t have time to read everything out there? Then be sure to follow Dr. Brian Durie’s Week in Review blog. The leading myeloma expert and IMF Chairman of the Board drills down on a wide range of topics – from the latest myeloma research results to the environmental issues that offer insight into prevention. He sifts through the data to deliver the bottom line.
For more than a decade, the International Myeloma Foundation has attended the American Society of Hematology (ASH) annual meeting, an exciting convergence of more than 30,000 health-care professionals from around the world. Explore this page to learn about the latest blood cancer research from the meeting, especially key clinical trials to advance the treatment and management of multiple myeloma
The support of loved ones allows us to continue to fund efforts to search for a cure. Check out how Fundraisers are helping in the fight against myeloma.
